Finland Times

 

Press Release Image.

A Finnish biopharmaceutical company is selected for the first time to present at the Cavendish Global Health Impact Forum scheduled for May 10 to 14 in the USA. 

 

The Oulu-based Paras Biopharmaceuticals Finland Oy, an upcoming manufacturer of biosimilars and therapeutic peptides, will take part in the forum at La Jolla, California, the company said in a press release on Tuesday.

 

The purpose of the forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programmes within health and the life sciences, the release said.

 

Cavendish impact forums are hosted by leading institutions across the globe including the University of California, San Diego, the J. Craig Venter Institute, the Scripps Research Institute, the Sanford-Burnham Medical Research Institute, the Sanford Consortium for Regenerative Medicine, and the Institute of the Americas.

 

“The theme of our La Jolla, California Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World,’” explained Michael Moffat, Cavendish co-founder and chief executive officer.

 

Moffat said, “With the help of our expert advisers, we conduct a global search of research institutions and private-sector companies in order to identify organisations that meet the required standard of excellence.

 

“The quality and originality of Paras Biopharmaceuticals’ technologies (Diabrid Technology, Noble Cleav Technology and Biomultifold Microbial High Expression Technology) and scientific insights for the development of affordable biologicsallows made a major contribution in targeting therapeutic areas, such as osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.”

 

In a way of response, Director of Global Strategic Alliance at Paras Biopharmaceuticals Dr Hans Soderlund said, “We are honoured to be selected as the first Finnish company (and only the second company in the Nordic region) to present at this unique event. [It’s a] recognition of our efforts for the effective production of recombinant therapeutics to provide affordable healthcare affecting populations around the world.” 

 

“In a time of widespread economic austerity and increased pressure on Governments’ health budgets, demand for access to affordable healthcare is greater than ever. We welcome the opportunity to interact with many of the world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world,” said Dr Ashesh Kumar, director of Biologics and Licensing at the company. 

 

Based in Oulu, Paras Biopharmaceuticals is an award-winning, privately-held Finnish company focused on developing biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides.

 

The facilities of the company (European GMP US-FDA compliant) in Finland are dedicated to the development, scale-up and GMP production of recombinant products for osteoporosis, rheumatoid arthritis, metabolic disorders (diabetes) and oncology.

 

Cavendish Global consists of leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavours within health and the life sciences.

 

The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  

 

The forum is also an opportunity for family offices to champion and share information on projects and organisations they are passionate about with other family offices from around the world. A unique gathering of leading family offices, Cavendish Impact Forums take place thrice a year.